Guizhou Bailing Group Pharmaceutical Co Ltd (002424) - Net Assets
Based on the latest financial reports, Guizhou Bailing Group Pharmaceutical Co Ltd (002424) has net assets worth CN¥3.20 Billion CNY (≈ $468.57 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.95 Billion ≈ $871.40 Million USD) and total liabilities (CN¥2.75 Billion ≈ $402.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guizhou Bailing Group Pharmaceutical Co (002424) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.20 Billion |
| % of Total Assets | 53.77% |
| Annual Growth Rate | 17.19% |
| 5-Year Change | -19.83% |
| 10-Year Change | 3.57% |
| Growth Volatility | 89.27 |
Guizhou Bailing Group Pharmaceutical Co Ltd - Net Assets Trend (2007–2025)
This chart illustrates how Guizhou Bailing Group Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Guizhou Bailing Group Pharmaceutical Co defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual net assets of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025. For live valuation and market cap data, see 002424 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.17 Billion ≈ $464.57 Million |
-0.76% |
| 2024-12-31 | CN¥3.20 Billion ≈ $468.14 Million |
-9.30% |
| 2023-12-31 | CN¥3.53 Billion ≈ $516.15 Million |
-11.75% |
| 2022-12-31 | CN¥4.00 Billion ≈ $584.87 Million |
+0.93% |
| 2021-12-31 | CN¥3.96 Billion ≈ $579.50 Million |
+1.02% |
| 2020-12-31 | CN¥3.92 Billion ≈ $573.66 Million |
-5.22% |
| 2019-12-31 | CN¥4.14 Billion ≈ $605.25 Million |
+5.39% |
| 2018-12-31 | CN¥3.92 Billion ≈ $574.31 Million |
+13.20% |
| 2017-12-31 | CN¥3.47 Billion ≈ $507.36 Million |
+13.11% |
| 2016-12-31 | CN¥3.07 Billion ≈ $448.56 Million |
+14.34% |
| 2015-12-31 | CN¥2.68 Billion ≈ $392.31 Million |
+14.19% |
| 2014-12-31 | CN¥2.35 Billion ≈ $343.57 Million |
+10.37% |
| 2013-12-31 | CN¥2.13 Billion ≈ $311.30 Million |
+4.15% |
| 2012-12-31 | CN¥2.04 Billion ≈ $298.89 Million |
+5.27% |
| 2011-12-31 | CN¥1.94 Billion ≈ $283.94 Million |
+5.05% |
| 2010-12-31 | CN¥1.85 Billion ≈ $270.28 Million |
+393.30% |
| 2009-12-31 | CN¥374.42 Million ≈ $54.79 Million |
+42.50% |
| 2008-12-31 | CN¥262.75 Million ≈ $38.45 Million |
+43.83% |
| 2007-12-31 | CN¥182.68 Million ≈ $26.73 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guizhou Bailing Group Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5005.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.49 Billion | 47.21% |
| Other Components | CN¥1.67 Billion | 52.79% |
| Total Equity | CN¥3.16 Billion | 100.00% |
Guizhou Bailing Group Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Guizhou Bailing Group Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KSB SE & Co. KGaA
F:KSB3
|
$871.43 Million |
|
DoubleU Games Co Ltd
KO:192080
|
$871.49 Million |
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
$871.72 Million |
|
Barings BDC Inc
NYSE:BBDC
|
$871.77 Million |
|
Pearl Global Industries Limited
NSE:PGIL
|
$870.81 Million |
|
Hnac Technology Co Ltd
SHE:300490
|
$870.40 Million |
|
Zhongtong Bus Holding Co Ltd
SHE:000957
|
$870.21 Million |
|
Ningbo Henghe Mould Co Ltd
SHE:300539
|
$870.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guizhou Bailing Group Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,181,166,740 to 3,155,519,418, a change of -25,647,322 (-0.8%).
- Net loss of 104,366,045 reduced equity.
- Dividend payments of 62,476,806 reduced retained earnings.
- Other factors increased equity by 141,195,529.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-104.37 Million | -3.31% |
| Dividends Paid | CN¥62.48 Million | -1.98% |
| Other Changes | CN¥141.20 Million | +4.47% |
| Total Change | CN¥- | -0.81% |
Book Value vs Market Value Analysis
This analysis compares Guizhou Bailing Group Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 24.80x to 1.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.17 | CN¥4.26 | x |
| 2008-12-31 | CN¥0.25 | CN¥4.26 | x |
| 2009-12-31 | CN¥0.57 | CN¥4.26 | x |
| 2010-12-31 | CN¥1.44 | CN¥4.26 | x |
| 2011-12-31 | CN¥1.35 | CN¥4.26 | x |
| 2012-12-31 | CN¥1.43 | CN¥4.26 | x |
| 2013-12-31 | CN¥1.48 | CN¥4.26 | x |
| 2014-12-31 | CN¥1.65 | CN¥4.26 | x |
| 2015-12-31 | CN¥1.87 | CN¥4.26 | x |
| 2016-12-31 | CN¥2.13 | CN¥4.26 | x |
| 2017-12-31 | CN¥2.40 | CN¥4.26 | x |
| 2018-12-31 | CN¥2.68 | CN¥4.26 | x |
| 2019-12-31 | CN¥2.87 | CN¥4.26 | x |
| 2020-12-31 | CN¥2.81 | CN¥4.26 | x |
| 2021-12-31 | CN¥2.66 | CN¥4.26 | x |
| 2022-12-31 | CN¥2.88 | CN¥4.26 | x |
| 2023-12-31 | CN¥2.54 | CN¥4.26 | x |
| 2024-12-31 | CN¥1.89 | CN¥4.26 | x |
| 2025-12-31 | CN¥2.26 | CN¥4.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guizhou Bailing Group Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.42%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 1.96x
- Recent ROE (-3.31%) is below the historical average (11.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 39.41% | 16.11% | 0.90x | 2.73x | CN¥53.66 Million |
| 2008 | 30.56% | 13.35% | 1.03x | 2.22x | CN¥54.02 Million |
| 2009 | 29.82% | 15.35% | 0.89x | 2.19x | CN¥74.22 Million |
| 2010 | 8.57% | 18.32% | 0.31x | 1.52x | CN¥-26.50 Million |
| 2011 | 10.89% | 18.30% | 0.38x | 1.58x | CN¥16.95 Million |
| 2012 | 10.95% | 16.21% | 0.42x | 1.60x | CN¥19.31 Million |
| 2013 | 12.80% | 19.18% | 0.40x | 1.65x | CN¥59.02 Million |
| 2014 | 13.37% | 19.72% | 0.44x | 1.54x | CN¥78.30 Million |
| 2015 | 15.54% | 21.66% | 0.49x | 1.45x | CN¥146.70 Million |
| 2016 | 15.96% | 21.78% | 0.52x | 1.40x | CN¥180.17 Million |
| 2017 | 15.39% | 20.30% | 0.54x | 1.41x | CN¥184.16 Million |
| 2018 | 14.55% | 17.96% | 0.52x | 1.54x | CN¥176.22 Million |
| 2019 | 6.98% | 9.92% | 0.40x | 1.74x | CN¥-122.44 Million |
| 2020 | 3.91% | 4.93% | 0.44x | 1.81x | CN¥-237.01 Million |
| 2021 | 3.01% | 3.81% | 0.48x | 1.65x | CN¥-275.65 Million |
| 2022 | 3.47% | 3.91% | 0.51x | 1.73x | CN¥-260.99 Million |
| 2023 | -11.80% | -9.72% | 0.58x | 2.09x | CN¥-765.75 Million |
| 2024 | 1.06% | 0.88% | 0.54x | 2.24x | CN¥-284.49 Million |
| 2025 | -3.31% | -3.42% | 0.49x | 1.96x | CN¥-419.92 Million |
Industry Comparison
This section compares Guizhou Bailing Group Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guizhou Bailing Group Pharmaceutical Co Ltd (002424) | CN¥3.20 Billion | 39.41% | 0.86x | $871.22 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others The company offers medicines in various forms, including tablets, capsules, granules, syrups, powders, pills, dews, pastes, sprays, and oral liquids, as well as wines … Read more